Four medicines accepted for use by NHS Scotland
13th April 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
Firstly, Sanofi s Sarclisa (isatuximab) has been accepted by the SMC for the treatment of relapsed or refractory multiple myeloma, in combination with two other medicines - pomalidomide and dexamethasone.
This treatment was accepted following consideration through the SMC s Patient and Clinician Engagement (PACE) process, which is used for medicines for end of life and rare conditions.
Another medication developed by Sanofi - Dupixent (dupilumab) - was also accepted for use on NHS Scotland, for the treatment of a subgroup of patients with severe asthma.
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
SMC approves funding for four new medicines on the NHS
9th February 2021
In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland.
Bristol Myers Squibb’s (BMS) multiple sclerosis (MS) oral therapy Zeposia (ozanimod) has been accepted for the treatment of relapsing-remitting MS (RRMS).
Zeposia is used in RRMS patients with active disease, where patients have relapses or signs of active inflammation on scans.
Also approved for use by NHS Scotland was AbbVie’s JAK inhibitor Rinvoq, which has been accepted for the treatment of severe rheumatoid arthritis that is inadequately controlled by disease-modifying anti-rheumatic drugs (DMARDS).
Normal, IL, USA / www.cities929.com
Feb 4, 2021 12:11 PM
(The Center Square) A legal action group is requesting a state medical board revoke the medical license of Illinois’ top doctor – Dr. Ngozi Ezike – over the state’s handling of the COVID-19 pandemic.
Justin Mahwikizi, executive director of The American Institute of Action, requested the Medical Disciplinary Board conduct an investigation into Ezike’s medical license, in a letter to the Illinois Department of Financial and Professional Regulation s Division of Professional Regulation Complaint Intake Unit.
Mahwikizi is seeking revocation of Ezike’s license.
“The Doctor Engaged in dishonorable, unethical or unprofessional conduct of a character likely to deceive, defraud or harm the public,” the seven-page letter states.